US 12,435,149 B2
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
Darren L Bates, Oak Park, CA (US); Donghui Shi, Thousand Oaks, CA (US); David J. Lloyd, Thousand Oaks, CA (US); Pavel Bondarenko, Thousand Oaks, CA (US); Mark L Michaels, Encino, CA (US); Todd Hager, Agoura Hills, CA (US); Xiaoshan Min, Burlingame, CA (US); Aiko Umeda, Woodland Hills, CA (US); Irwin Chen, Los Angeles, CA (US); and Zhulun Wang, Palo Alto, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Appl. No. 16/623,750
Filed by AMGEN INC., Thousand Oaks, CA (US)
PCT Filed Jun. 20, 2018, PCT No. PCT/US2018/038638
§ 371(c)(1), (2) Date Dec. 17, 2019,
PCT Pub. No. WO2018/237097, PCT Pub. Date Dec. 27, 2018.
Claims priority of provisional application 62/522,559, filed on Jun. 20, 2017.
Prior Publication US 2021/0087286 A1, Mar. 25, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 38/26 (2006.01)
CPC C07K 16/2869 (2013.01) [A61K 38/26 (2013.01); A61K 9/0019 (2013.01); C07K 2317/21 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01)] 49 Claims
 
1. An isolated antigen binding protein that specifically binds to a human gastric inhibitory peptide receptor (GIPR) polypeptide, wherein said antigen binding protein is an antibody or a fragment thereof, wherein the fragment is a Fab fragment, a Fab′ fragment, or a F(ab′)2 fragment, and wherein said antibody is a GIPR antagonist and comprises a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3, wherein each CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3, respectively, comprises SEQ ID NO: 1290, SEQ ID NO: 1291, SEQ ID NO: 1292, SEQ ID NO: 1293, SEQ ID NO: 1294, and SEQ ID NO: 1295.